HIV, Lenacapavir and Data

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
MIT Technology Review10h
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
PharmExec11h
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Montgomery Advertiser on MSN12h
Alabama still fighting HIV: 'In the South is where we have the majority of the problems':
Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
The American Journal of Managed Care1d
Bridging Gaps in HIV Care Through Pharmacy-Based Solutions
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute ...
Leading HIV advocate David Polson farewelled at state memorial in Sydney
Prominent HIV advocate David Polson, who was was one of the first 400 men diagnosed with HIV in Australia in the 1980s, has ...
STAT1d
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
The American Journal of Managed Care2d
Couples Counseling Key to HIV Prevention and Maternal Care
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...
Scientists develop yearly HIV injection: How it could help millions
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...